Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
B-cell acute lymphoblastic leukemia Indication Strategy Report 2026: CD19, Trials and Deals
23 July 2026
2026 B-cell acute lymphoblastic leukemia strategy: epidemiology, CD19 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
T-cell acute lymphoblastic leukemia Indication Strategy Report 2026: NOTCH1, Trials and Deals
23 July 2026
2026 T-cell acute lymphoblastic leukemia strategy: epidemiology, NOTCH1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Mixed phenotype acute leukemia Indication Strategy Report 2026: BCL2, Trials and Deals
23 July 2026
2026 Mixed phenotype acute leukemia strategy: epidemiology, BCL2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Blastic plasmacytoid dendritic cell neoplasm Indication Strategy Report 2026: CD123, Trials and Deals
23 July 2026
2026 Blastic plasmacytoid dendritic cell neoplasm strategy: epidemiology, CD123 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cancer of unknown primary Indication Strategy Report 2026: PD-1, Trials and Deals
23 July 2026
2026 Cancer of unknown primary strategy: epidemiology, PD-1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Thymoma Indication Strategy Report 2026: KIT, Trials and Deals
23 July 2026
2026 Thymoma strategy: epidemiology, KIT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap MCP…
Latest Hotspot
8 min read
Nonseminomatous germ cell tumor Indication Strategy Report 2026: KIT, Trials and Deals
23 July 2026
2026 Nonseminomatous germ cell tumor strategy: epidemiology, KIT biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Seminoma Indication Strategy Report 2026: KIT, Trials and Deals
23 July 2026
2026 Seminoma strategy: epidemiology, KIT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with PatSnap…
Latest Hotspot
8 min read
Yolk sac tumor Indication Strategy Report 2026: AFP, Trials and Deals
23 July 2026
2026 Yolk sac tumor strategy: epidemiology, AFP biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Ovarian germ cell tumor Indication Strategy Report 2026: KIT, Trials and Deals
23 July 2026
2026 Ovarian germ cell tumor strategy: epidemiology, KIT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Chondroblastoma Indication Strategy Report 2026: H3F3B, Trials and Deals
23 July 2026
2026 Chondroblastoma strategy: epidemiology, H3F3B biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Giant cell tumor of bone Indication Strategy Report 2026: RANKL, Trials and Deals
23 July 2026
2026 Giant cell tumor of bone strategy: epidemiology, RANKL biology, clinical competition, recent deals, unmet need and market attractiveness.